Illumina launches TruPath Genome sequencing technology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Illumina launches TruPath Genome, setting a new standard in genomic insight
February 24, 2026 12:15 PM ESTTruPath Genome offers more complete genome, with the simplest sample to sequencer workflow
Data presented at AGBT demonstrates TruPath Genome's accuracy in detecting rare genetic disease
Broad Clinical Labs is among first to adopt product, which was previously known as "constellation mapped read technology"
SAN DIEGO, Feb. 24, 2026 /PRNewswire/ --Â Illumina, Inc. (NASDAQ: ILMN) today announced the launch of... More
